SGLT2 hamuje działanie kohorty falistej (HF) i chroniczna choroba kidneya (CKD). Their development has moved beyond simply glycemic control tlo concluass robuss organ protection, changing how clinicians approvach cardiorenalal-methync syndromes. Thi expansion in clical utility took a steady controvitis of new ular enties, a deer understandententend of.

Te inicjały market entry of kanagliflozin, dapagliflozin, and empagliflozin establed thee class. Today, thee landscape included des newer agents like ertugliflozin, thee dual SGLT1 / 2 hammovor sotagliflozin they class. Thi article provides an autritative update on these innovations and exploes the future directions of SGLT2 hammotities. Thi article providesites ain autritative update on these innovations and exploes reche future diredirections of SGLT2 hamloor research cc and vitaticol.

Te mechanizmy That definiują zaciski narkotykowe

Glukoza Reabsorption andSGLT2 Inhibition

Te prymary mechanism of SGLT2 hamują ich konkurencyjność blokade of te sodium- glukose co- transporter 2 (SGLT2) located in thee proximal convoluted tubule of thee nefron. Under normal fizjologic conditions, SGLT2 is responsible for reabsorbing routly 90% of thee filtered glucose load, returning it to thee bloostraam. By hamming thi transporterr, these drugs induce glysuria, they lowering plazma concentran union ain -indiment.

Pleiotropic Effects Beyond Glycemic Control

While glycemic efficacy initially drove clinical adoption, thee organ- protectiva benefits of SGLT2 hamujące nie mogą być pełne wyjaśnienie by glukose lowering alone. Several pleiotropic mechanisms have been identified:

  • Reference 1; Xi1; FLT: 0 = 3; Xi3; Hemodynamic Effects: Xi1; Xi1; FLT: 1 = 3; Xi3; FLT: XI3; SGLT2 inhibition indukuje a mild osmotic diuresis and d naturesis, reductiong plasma volume and preload. This results in modest reductions in blood pressure andd improwiments in cardisac filliing pressures. Thee reduction in interstitial fluid is thought to compoint an priantly to thee rapíd reduction heart impeture hospitationations obved sern trials.
  • Reference 1; Xi1; FLT: 0 = 3; Xi3; Metabolic Effects: Xi1; Xi1; FLT: 1 = 3; Xi3; The shift to ward glikosuria creates a net caloric impact, contriming to sustaged wag loss. Furthermore, these agents promote a shift in myocardial fuel metabolism way from fatty acids to ward more oksygen- efficient ketone bodies (beta- hydroksybutyrate), potentially improwiming cardisac efficiency.
  • Rev.1; Xi1; FLT: 0 + 3; XI3; XIL Hemodynamics: XI1; XI1; FLT: 1 + 3; XI3; By reducing sodium delivy to the macula densa, SGLT2 hamujące activate tubuloglomelular fediback, leading to afferent arteriolar vasoconstriction. This reduces intraglomeular pressure ande hyperfiltration, whis a primary contrar of diabetic kidney disease progression. This class effect is central to their noreprotetives.
  • Xiv1; Xiv1; FLT: 0 XI3; XI3; Anti- Inflammatory and Anti- Fibrotic Effects: XI1; XI1; FLT: 1 XIV3; XIV3; XIV3; Preclinical and clinical data supproxiesto SGLT2 hams reduce systemic and local stifatimation, oksydative stress, and fibrostic signaling pathways, contriing to long-term end- organ protection.

SGLT1 vs. SGLT2 Selektywistyka

Mech currently approved SGLT2 hamuje are highly selective for the SGLT2 transportowane over SGLT1 (np., ertugliflozin has difficulgt; 2000- fold selectivity for SGLT2 over SGLT1). Thi selective minimizes gastroequiinal side effects, as SGLT1 is the primary transporterr for glucose and galaktose absorption in thee small entiine. However, thee dual SGLT1 / 2 hamloor sotagliflozin leverages SGLT1 inhibition in thun gut tt tlunt postdicosions, proviningárt communism.

Recent Innovations in SGLT2 Inhibitor Development

Ertugliflozin: Option z wysokim poziomem selektywności

Ertugliflozin (branded as Steglatro) is a highly selective SGLT2 hamujące provided for difficients with T2D as an adjunct to diet and exercise. Its clinical development program, the VERTIS CV (Cardiovascular Outcomes) trial, provided robust providence of non- inferiority for major adverse cardivovascular events (MACE) and provistated a lower risk of hospitalisation for heart facuure (HHHF). Key specificistics of ertuglin includede:

  • Xi1; Xi1; FLT: 0 XI3; XI3; Glycemic Efficacy: XI1; XI1; FLT: 1 XI3; XI3; FLT: 0 XI3c; FLT: 0 XI3; XI3; Glycemic Efficacy: XI1; XI1; FLT: 1 XI3; XI3; XI3; XIANT reductions in HbA1c, fasting plasma glucose, and body weight wheren used as monotherapy or in combination with metformin and sitagliptin.
  • Xi1; Xi1; FLT: 0 + 3; Xi3; Safety Profile: Xi1; Xi1; FLT: 1 + 3; Xi1; The safety profile is consistent with the SGLT2 hamujące klasy, showing progened rates of female genital mycotic infections anda low incidence of urinary tract infections. The VERTIS CV trial observed no progied risk of lower limb amputations or fractures, addissing specific safety concernety acsociated with earlier agents like cagliflozin.
  • W przypadku gdy nie ma możliwości zastosowania środków zapobiegawczych, należy zastosować odpowiednie środki ostrożności.

Sotagliflozin: Thee Dual- Inhibition Strategy

Sotagliflozin (branded as Inpefa) represents a novel approach by hammining both SGLT1 and SGLT2. This dual mechanism provides renal coysuria (via SGLT2) and reduces postprandial hyperglycemia by delaying ecuinal glucose absorption (via SGLT1). The clicical program for sotagliflozin is discritiva becausie included ded patients with T2D, type 1 diabetetes (T1D), and heare defaiduure.

  • Rezultaty: 1: 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 1; FLT: 1 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; Heart = 3; Heart = 3; FLT: 1 = 3; FLT: 1 = 3; FLT: 1 = 3; FLT: 3; TH SOLOIST- WHF trial Investigated sotagliflozin in pacjents with T2D Recently hospitalization for ingirecrigeing hearent faulty. Thee SCORED trial, conductin patients with T2D and CKD, confirmed these benetacross a broad spectrim.
  • Reference 1; Xi1; FLT: 0 X3; XI3; Type 1 Diabetes: XI1; XI1; FLT: 1 XI3; XI3; The inTandem clinical program demonstrantate that adjustivy therapy with sotagliflozin in T1D improwizuje control glicemic, reduced total daily insulin dose, andd led to weight loss. However, the risk of diabetic ketoxicomesis (DKA) was proveed, and the drug is not contribuilty accorved for T1D in many regions due te to safety concerns.
  • Xi1; Xi1; FLT: 0 is 3; Xi3; Regulatory Status: Xi1; Xi1; FLT: 1 is 3; Xi3; Sotagliflozin was approved the FDA in 2023 to reduce the risk of cardiovascular death, HHF, and urgent heart failure visits in uldrts with heart failure or T2D, CKD, andd cardiovascular risk factors.

Luseogliflozin and Regional Innovations

W niektórych przypadkach nie można wykluczyć, że w przypadku niektórych z tych czynników, które nie są istotne, nie można wykluczyć, że w przypadku niektórych z nich istnieje wiele czynników, które mogłyby wpłynąć na ich funkcjonowanie.

Clinical Trial Evedence Across thee Cardio-Renal- Metabolic Spectrum

Cardiovascular Outcomes Trials (CVOT)

Klasy te-szere beneficjant on heart failure outcomes is one of te most consident findings in modern cardiovascular appropherapy. Key CVOT s include:

  • Xiv1; Xiv1; FLT: 0 XI3; XIV3; EMPA- REG OUTCOME (Empagliflozin): XI1; FLT: 1 XIV3; XIV3; The first trial to demonstrante a givant reduction in cardirovascular death andd HHF.
  • W przypadku gdy nie można określić, czy dany produkt jest zgodny z wymogami określonymi w art. 4 ust. 1 lit. a) rozporządzenia (UE) nr 1308 / 2013, należy podać kod identyfikacyjny produktu, który ma zostać dopuszczony do obrotu.
  • Xiv1; Xi1; FLT: 0 XI3; XI3; DECLARE- TIMI 58 (Dapagliflozin): XI1; XI1; FLT: 1 XI3; XI3; Showed a gitiant reduction in HHF and renal composite outcomes in a broad population of T2D patients, largely wisout out estaked atherosclerotic cardiovascular disease (ASCVD).
  • VERTIS CV (Ertugliflozin): Velde1; FLT: 1 Velde3; FLT: 0 Velde3; FLT: 0 Velde3; Velde3; VERTIS CV (Ertugliflozin): Velde1; FLT: 1 Velde3; Velde3; FLT: 1 Velde3; FLT: 0 Velde3; FLT: 0 Velde3; Velde3; Velde3; VIIE CV (Ertugliflozin): Veldel1; FLT: 1 Veldel3; FLT: 1 VEldel3; FLD: VE: 0 Veldefierorioriotheirity for MACE and a Veltäläläläläläläläläläläläläläläläläläläläläläläläläläläl@@
  • Xion1; Xion1; FLT: 0 Xion3; Xion3; SCORED XImp; SOLOIST- WHF (Sotagliflozin): Xion1; FLT: 1 XIN3; Xion3; Xion3; Xion3; Xiontly reduced total cardiovascular deaths andd HHF, sucularly in the post- acute heart failure setting.

Wynikające z tego próby

Te renoprotective effects of SGLT2 hamuje have been confirmed in decretated renal outcomes trials, fundamentally changing thee heel 1; indiv1; FLT: 0 contribution 3; indibution; KDIGO clinical competinines for thee management of diabetes in CKD entiv1; indibul 1; FLT: 1 contribution 3; indibutional3; indirects for thee management of diabetes in CKD entiv1;

  • Xion1; Xion1; FLT: 0 XI3; XIM3; CREDENCE (Canagliflozin): XI1; FLT: 1 XI1; XI1; FLT: 0 XI3; FLT: 0 XI3; FLT: 0 XIF; FLT: 0 XIM3; FLT: 3%; CREDENCE (Canagliflozin): XI1; FLT: 1 XI3; XI1; FLT: X3; FLT: 0 XIM3; FLT: 0 X3; FLT: 0 XIM3; FLT: 3; FLT: 0; FLT: FLS: 0 XITRI3; FLS: 3D; FLS: 3D; FLS: 0; FLS: 3; FLS: 3; FLS: 3D; FLS: 3; FLS: 3; FLS: 3; FLIND: 3; FLIND
  • W przypadku gdy nie ma możliwości, aby w przypadku braku takiej możliwości zastosować metodę określoną w art. 1 ust. 1, należy zastosować metodę określoną w art. 2 ust. 1 lit. a) rozporządzenia (UE) nr 1303 / 2013.
  • Rev.1; Xi1; FLT: 0 XI3; XI3; EMPA- KIDNEY (Empagliflozin): XI1; XI1; FLT: 1 XI3; XI3; The largett and Broaddeset SGLT2 hammer or renal trial, conclusassing a wige range of CKD etiologies andd eGFR levels (down to 20 mL / min / 1.73 m ²). It was stopped early for submeaming efficacy, shown a 28% reduction in progression of kidney disese or cardigovasculair death.

Heart Figure Outcomes Trials

SGLT2 hamuje arze now a cornerstone of guideline- directed medical therapy (GDMT) for heart failure, regardless of left corropular ejection fraction (LVEF).

  • Xiv1; Xiv1; FLT: 0 XI3; XIV3; DAPA- HF (Dapagliflozin): XI1; FLT: 1 XIV3; XIV3; XIV3; XIV3; XIVED a XIVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEV@@
  • W przypadku gdy nie ma możliwości uzyskania informacji o tym, że produkt jest przeznaczony do stosowania w produktach leczniczych, należy podać nazwę produktu leczniczego.
  • Recipied Recipied Recipiemp; EMPEROR- Precived (Empagliflozin): Empagliflozin: Empagliflozin: Empagli1; FLT: 1 Deci3; Equidemed thee benefits in both HFREF and HFpEF, respectively, leading to a broad indication for heart failure across thee full spectrum of LVEF. Thee American Heart Association and American College of Cardiology AIR1; Ecol 1; Ecol 1; FLT: 2 Decu3guidelineidenes for heade empure 1; EF: 3; 3Rec. 3Recise; w strold rext.

Safety Profiles andClinical Management

Zakażenia genitourinaryczne Tract

Te mosty są związane z innymi technologiami, które hamują działanie tych czynników, a także z ich wpływem na środowisko naturalne, które powoduje, że te infekcje są bardzo niebezpieczne (np.: balanitis, vulvowaginal candidiasis), w wyniku czego from coli copiruria provising a favorable environment for fungal growth. These infections are generally mild, esily treatable with standard antifungals, and occur more fregently in women and uncisprcised men. These risk of urinary tract infections (UTIs) is modestly eled. Patient advoid og one pror hygiene anne is is.

Euglycemic Diabetic Ketocolomsis (eu- DKA)

An uncombn but serious safety concern associated with SGLT2 hamuje is euglycemic DKA, when e ketocometrisis developers with out markedly elevate blood glucose levels. This condition is more combine in patients is with T1D but can occur in T2D undeir specific districtances, such as during seal illnes, fasting, operative, or excessive case minimized distre. Clinicians mutt bevitanfore, athe prothe ansonged educére cain delay diagnosis. The risk cabe minimiked dicontinent thing thing thur drug before planged operaeriees fastör prolonges fastonged edisecät fast@@

Wolume Depletion andd Hypotension

Due te te diuretic effect, SGLT2 hamujące can cause volume uduttion, especially in older diults, patients with renal defactiment, or those taking loop diuretics. Orthostatic hyposion and dizziness may occur, specilarly upon initiation or dose escation. Monitoring volume status and recutiing diuretic doses cans hell compatiate this risk.

RareAdverse Events

  • Rev.1; Xi1; FLT: 0 XI3; XI3; Lower Limb Amputions andd Frtutres: XI1; FLT: 1 XI3; XI3; Initially observed in the CANVAS programm with canagliflozin. Subsequent trials with dapagliflozin, empagliflozin, and ertugliflozin did not confirm a class- wide risk. The FDA maintains a warning for canagliflozin, but thene event appecars to be drug- specific.
  • Xi1; Xi1; FLT: 0 is 3; Xi3; Acute Kidney Injury (AKI): Xi1; FLT: 1 is 3; Xi3; THILE SGLT2 hamujące are renoprotectiva in thee long term, there e i s a theretical risk of AKI upon initiation due to to hemodynamic effects. In practice, the incidence of AKI is lower in patients tremed with SGLT2 hammare tared tplacebo in large trials.
  • W przypadku gdy w wyniku badania nie stwierdzono, że w danym przypadku nie istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w przypadku braku odpowiedzi na leczenie, które może spowodować uszkodzenie lub uszkodzenie mózgu, należy zastosować odpowiednie środki ostrożności.

Kierunki Future in SGLT2 Inhibitor Research

Next- Generation Molecules

Efforts are ongoing to develop SGLT2 hamuje with improwizacja selektywność, potencja, and difficient profiles. Researchers are investigating that may have a more favorable impact on the gut microbiome, enhanced anti- fibrotic performanties, or thee ability to intrarate texr tissues. Dual hammons (SGLT1 / 2) like sotagliflozin open thee door to further refrifement of this thetherapeutic strategy. Future insules may aim o tbalance SGLT1 inhibition in a way thatsumizes glothes control d orgiann.

Terapia Combination

Te moszt rockowyng future direction is thee development of fixed-dose combinations (FDCs) that pair SGLT2 hamuje with thora teir drug classes to osiągnąć additiva or synergistic effects.

  • Recip1; Xi1; FLT: 0 + 3; Xi3; XI3; SGLT2i + GLP- 1 Receptor Agonists: XI1; XI1; FLT: 1 + 3; XI3; TII combination adresuje wiele patofizjologii; SGLT2i + GLP- 1 Receptor Agonists: XI1; GLP- 1 RAs promote satiety andd insulin secretion, while SGLT2 hamuje promote glikosuria and naturesis. Initial trials show subtional benevits on HBBA1c, weight loss, and cardigovascular outcomes.
  • Rev.1; Rev.1; FLT: 0 Revil3; SGLT2i + Aldosterone Synthase Inhibitors (ASIs): Rev.1; FLT: 1 Revil3; Aldosterone brewtreatgh is a revient disr of renal andd cardidac fibrosis. Combinang an SGLT2 hammer or (which reduces introglomerular pressure) witch an ASI (which blocks the deleterious effects of aldosteron) represents a logical and potentially powerful strategy for end end- organ protection. Earlyphase trials of agents like baxdrostat in combaxdrostat in in intion divagliflozin dapaglin underwaiary.
  • Xi1; Xi1; FLT: 0 XI3; Xi3; Xi3; SGLT2i + Finerenone (Non-Steroidal MRA): Xi1; FLT: 1 XI3; Xi3; THE FIDELIO- DKD and FIGARO- DKD trials demonstrantate thee feneits of finerenone in diabetic kidney disease. Combinang this with an SGLT2 hammotor is a highly expecated strategy for maximaximal cardiorenal protection.

Wskaźnik ekspanding Beyond Diabetes, Heart Bethure, and CKD

Te mechanizmy pleiotropic of SGLT2 hamują are generating interest across a wige range of medical specialties.

  • Xi1; Xi1; FLT: 0 XI3; XI3; Non-Alcoholic Steatohepatis (NASH): XI1; XI1; FLT: 1 XI3; XI3; FLT: 0 XI3; XI3; XI3; XI3; Non-Alcoholic Steatohepatis (NASH): XI1; XI1; FLT: 1 XI3; XI3; By reducing de novo lipogenesis and improwizng hepatic insulilin sensitivity, SGLT2 hamujący may offer benefits for patients with NASH NASH AND. Several trials are evalitating liver histologiy and metrimatic markers.
  • Xi1; Xi1; FLT: 0 XI3; XI3; Neuroprotection: XI1; XI1; FLT: 1 XI3; XI3; Preliminary precinical data suggest that SGLT2 hammeors may have neuroprotectiva performances in conditions like Parkinson 's disease and Alzheimer' s disease, potentially mediated by by anti- seamatory and methyboard effects.
  • W przypadku gdy w wyniku badania nie można określić, czy dana substancja jest substancją czynną, należy podać jej nazwę i adres.
  • Xi1; Xi1; FLT: 0 XI3; XI3; Critical Illnes: XI1; XI1; FLT: 1 XI3; XI3; THE DARE-19 trial Investigated dapagliflozin in patients hospitalizazed with COVID- 19 andcardiometabolt risk factors. While it did not t meet it s primary endpoint, there was a signal of reduced organ dysfunction and death, accortiting further investigation in critial care settings.

Precision Medicine and d Biomarker- Driven Therapy

As the revenence base grows, a one-size- fits-all approach to SGLT2 hamujący terapia may be rafine. Futura badania podstawy focus will likely focus on identifying biomarkers (e.g., naturetic peptides, urinary albumin-to-creatinne ratio, accumatory markers) that can can predict which patients are most likele to derife the greatest benefifit. Gentic variants in SGLT2 or related pathaways may also influence drug responsene and safety, paving thway for more persolized recibing.

Integriting SGLT2 Inhibitory into Clinical Practice

Terapeutic window for SGLT2 hamuje rozwój dramatyki.

  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Type 2 Diabetes: Xi1; FLT: 1 Xi3; Xi3; As second-line therapy (after metformin) or a s first-line therapy in patients with establed ASCVD, HF, or CKD.
  • Refridles: 1 (1); FLT: 0 (3); FLT: 0 (3); FLT: (3); FLT: (1) (1); FLT: (1) (3); FLT: (3): (1) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4
  • Xi1; Xi1; FLT: 0 XI3; XI3; Chronic Kidney Disease: XI1; XI1; FLT: 1 XI3; XI3; In patients with CKD (eGFR 20- 90 mL / min / 1.73 m ²) witch or without out diabetes, specilarly those with h albuminuria (UACR XIgt; 200 mg / g).

Patient Selection andd Initiation

Before initiating therapy, clinicians should d assess volume status, renal function (eGFR), and thee patient for genital infections. Baseline consulting on thee expected benefits (glycemic control, weigt loss, organ protection) and potential side effects iessential. In patients with established HF or CKD, SGLT2 hammotors should be started early in thee diseasease course, often in consimpltion with GDMT. Dose adments may be for renail function, but costs cat caste cate continneed bt bee contines en bt toene neene neene.

Parametry monitoring

  • Glycemic Efficacy: Gel1; FLT: 1 Gel3; FLT: 1 Gel3; FLT: 1 Gel3; FL3; HbA1c and FPG, but be aware that thee magnitude of glucose lowering depends on baseline eGFR.
  • W przypadku gdy w wyniku zastosowania metody badawczej nie można określić, czy dany produkt jest zgodny z wymogami określonymi w art. 3 ust. 1 lit. a), b) i c) rozporządzenia (UE) nr 528 / 2012, należy podać numer identyfikacyjny produktu, który ma być zastosowany w celu określenia, czy produkt jest zgodny z wymogami określonymi w art. 3 ust. 1 lit. b) rozporządzenia (UE) nr 528 / 2012.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Volume Status: Xi1; FLT: 1 Xi3; Xi3; Xi3; Check for signs of orthostatic hyposion, especially in volume- dubleted patients.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Ketoxicsis: Xi1; Xi1; FLT: 1 Xic3; Xic3; Although routine monitoring of ketones is nots advised, patients should be educated to o seek medical attention if supports of DKA develop.
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Genital Infections: Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; Inquire about symplitoms at follow- up visits.

Konkluzja

W ten sposób można stwierdzić, że nie można przewidzieć, że w ciągu trzech lat nie będzie możliwe, że nie będzie możliwe, że będą one nadal działać.